Clinical Trial Update: Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating lenvatinib plus nivolumab vs lenvatinib for advanced hepatocellular carcinoma with HBV infection was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Shi Ming | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: WITHDRAWN